Johnson & Johnson stopped a mid-stage test of its HIV vaccine in southern Africa after the shot showed insufficient ability to protect people from contracting the virus.
The trial, called Imbokodo, showed the vaccine was just 25% effective in preventing HIV infection over a period of two years, short of a goal of 50% efficacy, according to a statement. A similar vaccine developed by the drugmaker will continue being tested in Europe and the Americas in a final-stage study called Mosaico, Paul Stoffels, J&J’s chief scientific officer, said. ..If you have already registered or subscribed, please sign in to continue.
Tears grips my heart 😪knowing how hard& how much I’ve lost looking for good platform. I'll be guilty if i don't share this good news to people to join the best trader have ever know. Thanks for helping me and i will forever be grateful to you MarkHarry212 I got the R30k🥰
Law Law Latest News, Law Law Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: TheCitizen_News - 🏆 6. / 75 Read more »
Source: mailandguardian - 🏆 2. / 92 Read more »